Summary of Study ST003039

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001891. The data can be accessed directly via it's Project DOI: 10.21228/M88X46 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST003039
Study Title	A Non-Targeted Metabolomics Comparative Study on Plasma of Pfizer and Sinopharm COVID- 19 Vaccinated individuals, Assessed by (TIMS-QTOF) Mass Spectrometry.
Study Summary	COVID-19 is a contagious globally threatening infectious disease that accounted for an ongoing pandemic that manifested in multi-organs diseases and failures. The current study aimed to investigate the effectiveness of the Pfizer and Sinopharm vaccines in relation to metabolomic alterations and their association with immune pathways. The study employed a cross-sectional design and utilized an untargeted metabolomics-based approach. Plasma samples were collected from three groups: non- vaccinated participants, Sinopharm vaccinated participants, and Pfizer vaccinated participants. Comparative metabolomic analysis was performed using TIMS-QTOF, and a one-way ANOVA test was conducted using MetaboAnalyst Software. Out of the 105 detected metabolites, 72 showed statistically significant alterations (p<0.05) among the different groups. Several metabolites, including neopterin, pyridoxal, and syringic acid, were highly altered in individuals vaccinated with Pfizer. On the other hand, sphinganine, neopterin, and sphingosine were impacted in individuals vaccinated with Sinopharm. These metabolites could potentially serve as biomarkers for vaccine efficacy. Furthermore, both Pfizer and Sinopharm vaccinations were found to affect sphingolipid metabolism pathways and histidine metabolism pathways when compared to the control group. The Sinopharm group exhibited altered lysine degradation compared to the control group. When comparing the enriched pathways of the Pfizer and Sinopharm groups, purine metabolism was found to be affected. Additionally, perturbations in tryptophan metabolism and vitamin B6 metabolism were observed when comparing the Pfizer group with both the control and Sinopharm groups. These findings highlight the importance of metabolomics in assessing vaccine effectiveness and identifying potential biomarkers.
Institute	Sharjah Institute for Medical Research
Last Name	Facility
First Name	Core
Address	M32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah, Sharjah, UAE, Sharjah, 000, United Arab Emirates
Email	tims-tof@sharjah.ac.ae
Phone	+971 6 5057656
Submit Date	2024-01-02
Raw Data Available	Yes
Raw Data File Type(s)	d
Analysis Type Detail	LC-MS
Release Date	2024-01-31
Release Version	1

Select appropriate tab below to view additional metadata details:

Sample Preparation:

Sampleprep ID:	SP003159
Sampleprep Summary:	we used chloroform/methanol extraction protocol to increase the coverage of the extracted metabolites. At first, the samples (cells and buffer) were transferred into Eppendorf tubes then centrifuged at 14000 rpm for 5 min. Afterward, the buffer was discarded, and the cells were preserved. To each sample, 400 µL of the mixture containing one protease inhibitor tablet and 10 mL of lysis buffer was added. Following rest for 10 minutes, samples were transferred to 10 mL tubes, vortexed for 2–4 minutes, and sonicated with a COPLEY probe-sonicator (QSONICA SONICATOR, USA) for 30 seconds while utilizing a 30 % amplifier in an ice bath. The samples were then transferred to Eppendorf tubes and centrifuged for 5 minutes at 14000 rpm. The supernatant was then transferred to another Eppendorf, and 400 µL of methanol and 300 µL of chloroform were added. Following that, the samples were vortexed for 30 seconds and centrifuged for 5 minutes at 14000 rpm. After that, two metabolite-containing layers are obtained, after transferring the upper layer of each sample to glass vials, 400 µl of methanol was added, followed by vertexing and centrifugation. The remaining supernatant was transferred to the same glass vials used before for the drying step, with the remaining protein pellets being air-dried for proteomics. A dried metabolomics sample was resuspended in 200 µL (0.1% formic acid in water) and injected into HPLC to be analysed by Q-TOF MS.In summary, After dividing the samples into 100 µL portions in Eppendorf tubes, 300 µL of methanol from Wunstorfer Strasse, Seelze, Germany, was introduced. The tubes were subsequently vortexed and placed in an incubator at -20°C for two hours. Following incubation, the samples underwent another round of vortexing and were centrifuged for 15 minutes at 14000 rpm. The resulting supernatant was evaporated at 35 to 40 °C through speed vacuum evaporation. To assess the analysis's repeatability, a quality control (QC) sample was created by pooling the same volume of each sample (10µl). The extracted samples were then resuspended in 100 µL of Honeywell's LC-MS CHROMASOLV's 0.1% formic acid in Deionized Water (Wunstorfer Strasse, Seelze, Germany). Following that, 100 µL of the prepared sample was collected in an insert inside LC glass vials after filtration through a 0.45µm hydrophilic nylon syringe filter for LC-MS/MS analysis.

Sampleprep ID:

SP003159

Sampleprep Summary:

we used chloroform/methanol extraction protocol to increase the coverage of the extracted metabolites. At first, the samples (cells and buffer) were transferred into Eppendorf tubes then centrifuged at 14000 rpm for 5 min. Afterward, the buffer was discarded, and the cells were preserved. To each sample, 400 µL of the mixture containing one protease inhibitor tablet and 10 mL of lysis buffer was added. Following rest for 10 minutes, samples were transferred to 10 mL tubes, vortexed for 2–4 minutes, and sonicated with a COPLEY probe-sonicator (QSONICA SONICATOR, USA) for 30 seconds while utilizing a 30 % amplifier in an ice bath. The samples were then transferred to Eppendorf tubes and centrifuged for 5 minutes at 14000 rpm. The supernatant was then transferred to another Eppendorf, and 400 µL of methanol and 300 µL of chloroform were added. Following that, the samples were vortexed for 30 seconds and centrifuged for 5 minutes at 14000 rpm. After that, two metabolite-containing layers are obtained, after transferring the upper layer of each sample to glass vials, 400 µl of methanol was added, followed by vertexing and centrifugation. The remaining supernatant was transferred to the same glass vials used before for the drying step, with the remaining protein pellets being air-dried for proteomics. A dried metabolomics sample was resuspended in 200 µL (0.1% formic acid in water) and injected into HPLC to be analysed by Q-TOF MS.In summary, After dividing the samples into 100 µL portions in Eppendorf tubes, 300 µL of methanol from Wunstorfer Strasse, Seelze, Germany, was introduced. The tubes were subsequently vortexed and placed in an incubator at -20°C for two hours. Following incubation, the samples underwent another round of vortexing and were centrifuged for 15 minutes at 14000 rpm. The resulting supernatant was evaporated at 35 to 40 °C through speed vacuum evaporation. To assess the analysis's repeatability, a quality control (QC) sample was created by pooling the same volume of each sample (10µl). The extracted samples were then resuspended in 100 µL of Honeywell's LC-MS CHROMASOLV's 0.1% formic acid in Deionized Water (Wunstorfer Strasse, Seelze, Germany). Following that, 100 µL of the prepared sample was collected in an insert inside LC glass vials after filtration through a 0.45µm hydrophilic nylon syringe filter for LC-MS/MS analysis.